Antibiotic use in neonatal sepsis

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Pharmacology

Background:

• Neonatal sepsis presents with subtle, nonspecific signs, necessitating prompt intervention.
• Delayed treatment of neonatal sepsis can lead to fatal outcomes.
• Empirical antibiotic therapy is vital in suspected cases, initiated immediately after cultures are obtained.

Purpose of the Study:

• To outline optimal empirical antibiotic strategies for neonatal sepsis.
• To guide antibiotic selection based on onset (early vs. late) and suspected pathogens.
• To emphasize the importance of reassessing therapy based on culture results and clinical progress.

Main Methods:

• Review of current guidelines and literature on neonatal sepsis management.
• Analysis of common pathogens in early-onset and late-onset neonatal sepsis.
• Evaluation of antibiotic efficacy and resistance patterns for empirical therapy.

Main Results:

• Empirical therapy should cover Group B Streptococcus, Enterobacteriaceae, and Listeria monocytogenes in early-onset sepsis.
• Late-onset sepsis requires coverage for hospital-acquired pathogens like Staphylococci, Enterococci, and Pseudomonas aeruginosa.
• Combination therapy (e.g., penicillin/ampicillin with an aminoglycoside) is often effective, with specific agents recommended for nosocomial infections.

Conclusions:

• Antibiotic therapy should be tailored based on culture results and clinical response.
• Third-generation cephalosporins are generally not recommended for initial empirical therapy due to resistance concerns.
• Duration of therapy typically ranges from 10 to 14 days, adjusted for clinical improvement and infection severity.